Repligen | RGEN - Cash And Equivalent


Repligen reported $606.78M in Cash and Equivalent for its fiscal quarter ending in June of 2026.





Cash And Equivalent Change Date
Agilent USD 1.81B 49M Mar/2026
Align Technology USD 1.1B 42.76M Jun/2026
Bio Techne USD 209.82M 36.94M Mar/2026
BioMarin Pharmaceutical USD 874M 1.35B Jun/2026
Bristol-Myers Squibb USD 8.72B 852M Jun/2026
Bruker USD 184.9M 51.5M Jun/2026
Charles River Laboratories USD 192.02M 195K Jun/2026
Danaher USD 4.35B 1.35B Jun/2026
Dentsply International USD 239M 49M Jun/2026
General Electric Aerospace USD 9.35B 1.64B Jun/2026
Henry Schein USD 138M 18M Mar/2026
Illumina USD 1.09B 329M Mar/2026
IQVIA Holdings USD 1.91B 38M Jun/2026
Mettler Toledo International USD 51.38M 9.19M Jun/2026
Myriad Genetics USD 115.2M 9.2M Jun/2026
OraSure Technologies USD 160.58M 16.38M Jun/2026
Pacific Biosciences Of California USD 61M 4.73M Jun/2026
Pfizer USD 976M 727M Jun/2026
Repligen USD 606.78M 24.13M Jun/2026
Revvity USD 1.02B 162.62M Jun/2026
Standard Biotools USD 265.77M 147.56M Mar/2026
Thermo Fisher Scientific USD 3.25B 6.6B Mar/2026
Waters USD 539M 77M Jun/2026
West Pharmaceutical Services USD 435.8M 85.6M Jun/2026